The following impurities are available with SUMA Laboratories Pvt Limited. Click here to Download our impurities in pdf format...
Product list 51 - 100:
| S.No | Compound Name | CAS | Remarks |
|---|---|---|---|
| 51 |
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
C26H33F3O6 M.Wt.: 498.53 |
404830-45- | 15-Keto Travoprost |
| 52 |
2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)-N-methoxy-N-methylacetamide
C23H28N2O3 M. Wt.: 380.48 |
- NA - | Olopatadine impurity |
| 53 |
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetaldehyde
C21H24ClNO2 M.Wt.: 357.87 |
- NA - | Olopatadine Carbaldehyde. Hydrochloride |
| 54 |
5-(Diphenylphosphoryl)pentanoic acid
C17H19O3P M.Wt.: 302.30 |
71140-70-0 | Latanoprost impurity |
| 55 |
Methyl 5-(diphenylphosphoryl)pentanoate
C18H21O3P M.Wt.: 316.33 |
146964-27-4 | Latanoprost impurity |
| 56 |
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
C23H34O5 M.Wt.: 390.24 |
41639-83-2 | Latanoprost Acid |
| 57 |
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-5-phenylpentyl)cyclopentyl]hept-5-enoic acid
C23H32O5 M.W. 388.51 |
369585-22-8 | 15-Keto Latanoprost Acid |
| 58 |
5,6-trans-Latanoprost
C26H40O5 M.Wt.: 432.29 |
- NA - | 5,6-trans-Latanoprost |
| 59 |
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
C26H40O5 M.Wt.: 432.29 |
145773-22-4 | 15(S)-Latanoprost |
| 60 |
4,6-dichloro-2-methylsulfanylpyrimidine
C5H4Cl2N2S M.Wt.: 195.07 |
6299-25-8 | Alogliptin impurity |
| 61 |
4,6-dichloro-2-methylsulfonylpyrimidine
C5H4Cl2N2O2S M.Wt.: 227.07 |
4489-34-3 | Alogliptin impurity |
| 62 |
2-((4,6-Dichloropyrimidin-2-yloxy)methyl)benzonitrile)
C12H7Cl2N3O M.Wt.: 280.11 |
- NA - | Alogliptin impurity |
| 63 |
2-((4,6-Dimethoxypyrimidin-2-yloxy)methyl)benzonitrile
C14H13N3O3 M.Wt.: 271.27 |
- NA - | Alogliptin impurity |
| 64 |
2,2'-(((6-Chloropyrimidine-2,4-diyl)bis(oxy))bis(methylene))dibenzonitrile
C20H13ClN4O2 M.Wt.: 376.80 |
- NA - | Alogliptin impurity |
| 65 |
6-Chloro-2-(methylthio)pyrimidin-4-ol
C5H5ClN2OS M.Wt.: 176.62 |
- NA - | Alogliptin impurity |
| 66 |
2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
C15H21F3N2O2 M.Wt.: 318.33 |
917096-37-8 | Fluvoxamine impurity B |
| 67 |
1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate
C21H23NO3 M.Wt.: 337.17 |
6581-06-2 | Oxybutynin impurity |
| 68 |
methyl 2-hydroxy-2,2-diphenylacetate
C15H14O3 M.Wt.: 242.09 |
76-89-1 | Oxybutynin impurity |
| 69 |
4-(diethylamino)but-2-ynyl 2-hydroxy-2,2-diphenylacetate
C22H25NO3 M.Wt.: 351.18 |
14943-53-4 | Oxybutynin EP Impurity B |
| 70 |
4-[ethyl(methyl)amino]but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
C22H31NO3 M.Wt.: 357.23 |
1199574-70-3 | Oxybutynin Impurity C |
| 71 |
Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
C15H20O3 M.Wt.: 248.14 |
10399-13-0 | Oxybutynin Impurity 1 (Cyclohexyl Mandelic Acid Methyl Ester) |
| 72 |
Ethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
C16H22O3 M.Wt.: 262.16 |
31197-69-0 | Oxybutynin Impurity 2 (Phenylcyclohexylglycolic Acid Ethyl Ester) |
| 73 |
2-(1-cyanocyclohexyl)acetic acid
C9H13NO2 M.Wt.: 167.09 |
133481-09-1 | Gabapentin impurity B |
| 74 |
2-[1-[(3-oxo-2-azaspiro[4.5]decan-2-yl)methyl]cyclohexyl]acetic acid
C18H29NO3 M.Wt.: 307.21 |
1076198-17-8 | Gabapentin impurity D |
| 75 |
2-(cyclohexanecarbonyloxy)acetic acid
C9H13NO2 M.Wt.: 167.09 |
667465-00-1 | Gabapentin impurity E |
| 76 |
2-(1-(2-aminoethyl)cyclohexyl)acetic acid
C10H19NO2 M.Wt.: 185.14 |
1500558-49-5 | Gabapentin impurity G |
| 77 |
calcium;(3S,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
C33H35FN2O5 M.Wt.: 557.63 |
887196-25-0 | Atorvastatin related compound B |
| 78 |
calcium;(3R,5R)-7-[2,3-bis(4-fluorophenyl)-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
C33H33F2N2NaO5 M.Wt.: 597.61 |
693793-53-2 | Atorvastatin Related compound C |
| 79 |
4-[7-(4-fluorophenyl)-7-hydroxy-7a-phenyl-1a-(phenylcarbamoyl)-1b-propan-2-yl-4,5-dihydro-3H-oxireno[1,2]pyrrolo[4,5-b][1,3]oxazin-3-yl]-3-hydroxybutanoic acid
C33H34FN2NaO7 M.Wt.: 612.22 |
1316291-19-6 | Atorvastatin FXA Impurity (Atorvastation epoxy pyrrolooxazin 6-hydroxy analog) |
| 80 |
sodium;4-[1b-(4-fluorophenyl)-7-hydroxy-1a-phenyl-7a-(phenylcarbamoyl)-7-propan-2-yl-4,5-dihydro-3H-oxireno[1,2]pyrrolo[3,5-b][1,3]oxazin-3-yl]-3-hydroxybutanoate
C33H34FN2NaO7 M.Wt.: 612.22 |
1315629-79-8 |
Atorvastatin FX1 Impurity (Atorvastation epoxy pyrrolooxazin 7-hydroxy analog) |
| 81 |
5-(4-fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide
C33H33FN2O4 M.Wt.: 540.24 |
125995-03-1 | Atorvastatin related compound H |
| 82 |
4-(4-fluorophenyl)-2,4-dihydroxy-N,5-diphenyl-2-propan-2-yl-3,6-dioxabicyclo[3.1.0]hexane-1-carboxamide
C26H24FNO5 M.Wt.: 449.16 |
873950-19-7 | Atorvastatin Epoxy Tetrahydrofuran Analog |
| 83 |
3-(4-fluorobenzoyl)-2-(2-methylpropyl)-N,3-diphenyloxirane-2-carboxamide
C26H24FNO3 M.Wt.: 417.17 |
1246818-88-1 | Atorvastatin Oxirane Impurity |
| 84 |
Tert-butyl (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
C37H43FN2O5 M.Wt.: 614.32 |
134395-00-9 | Atorvastatin tert-Butyl Ester |
| 85 |
Bumetanide intermediate
C13H12N2O5S M.Wt.: 308.05 |
- NA - | Bumetanide intermediate |
| 86 |
3-(2-ethylhexylamino)-4-phenoxy-5-sulfamoylbenzoic acid
C21H28N2O5S M.Wt.: 420.17 |
153012-65-8 | Bumetanide impurity |
| 87 | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-prop-1-en-2-yl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
C29H28N6O5 M.Wt.: 540.21 |
879562-26-2 | Olmesartan - EP impurity C |
| 88 |
(2S)-2-(5-chloro-6-methoxynaphthalen-2-yl)propanoic acid
C14H13ClO3 M.Wt.: 264.06 |
89617-86-7 | Naproxen-EP-IMP-B |
| 89 |
(2S)-2-(5-iodo-6-methoxynaphthalen-2-yl)propanoic acid
C14H13IO3 M.Wt.: 355.99 |
116883-62-6 | Naproxen-EP-IMP-D |
| 90 |
(S)-2-(1-bromo-2-methoxynaphthalen-6-yl)propanoic acid
C14H13BrO3 M.Wt.: 308 |
84236-26-0 | Naproxen-EP-IMP-C |
| 91 |
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid;sodium
C20H21N5O6 M.Wt.: 427.15 |
937370-10-0 | D-Pemetrexed Disodium EP Imp. E |
| 92 |
5-(Propylsulphanyl)-1H-benzimidazol-2-amine
C10H13N3S M.Wt.: 207.08 |
80983-36-4 | Albendazole EP Impurity A |
| 93 |
Methyl N-[5-propylsulfinyl)-1H-benzo[d]imidazol-2-ylcarbamate
C12H15N3O3S M.Wt.: 281.08 |
54029-12-8 | Albendazole EP Impurity B |
| 94 |
Methyl N-(5-propylsulfonyl)-1H-benzo[d]imidazol-2-ylcarbamate
C12H15N3O4S M.Wt.: 297.08 |
75184-71-3 | Albendazole EP Impurity C |
| 95 |
2-Amino-1H-benzimidazole-5-yl)propyl-sulfanedione
C10H13N3O2S M.Wt.: 239.07 |
80983-34-2 | Albendazole EP Impurity D |
| 96 |
Methyl N(1H-benzo[d]imidazol-2-yl)carbamate
C9H9N3O2 M.Wt.: 191.07 |
10605-21-7 | Albendazole EP Impurity E |
| 97 |
Methyl –N-5-(methylsulfanyl)-1H-benzo[d]imidazol-2-ylcarbamate
C10H11N3O2S M.Wt.: 237.06 |
80983-45-5 | Albendazole EP Impurity F ( Under development ) |
| 98 |
Methyl N 5-chloro-1H-benzo[d]imidazol-2-ylcarbamate
C9H8ClN3O2 M.Wt.: 225.03 |
- NA - | Albendazole EP Impurity G |
| 99 |
Methyl N 5-(2-methyl-4-oxopentan-2-yl)sulfanyl-1H-benzo[d]imidazol-2-ylcarbamate
C15H19N3O3S M.Wt.: 321.11 |
- NA - | Albendazole EP Impurity H ( Under development ) |
| 100 | Methy N (5-propoxy-1H-benzo[d]imidazol-2-ylcarbamate
C12H15N3O3 M.Wt.: 249.11 |
20559-55-1 | Albendazole EP Impurity I |
Suma Laboratories ® All rights reserved.